Abstract
Several mechanisms of immune escape might be in operation in Epstein-Barr virus (EBV)-associated nasal NK/T-cell lymphoma. We have previously shown the downregulation of the immunogenic EBV nuclear antigens by alternative promoter usage and the preferential selection of the deletion genotype of latent membrane protein I in nasal lymphoma. To understand further the strategies used for immune escape by this tumor, we examined by immunohistochemistry HLA class I expression in 15 cases using frozen sections, along with β2-microglobulin and transporter associated with antigen processing I (TAPI) expression in 39 cases using paraffin sections. All nasal NK/T-cell lymphomas showed positive staining for HLA class I, β2-microglobulin and TAP I on most tumor cells, except for two cases (5%) in which most of the tumor cells lacked β2-microglobulin staining. We next immunostained for interleukin-10 on frozen sections in 13 cases, all of which showed strong expression by most tumor cells. Transcription of human interleukin-10 but not EBV BCRF I (viral interleukin-10) was identified by reverse transcriptase-polymerase chain reaction in these nasal NK/T-cell lymphomas. Overall, our data suggest that global downregulation of HLA class I or TAP I rarely accounts for the ability of nasal NK/T-cell lymphoma to evade immunosurveillance and that other immune escape mechanisms may be operating in nasal NK/T-cell lymphoma, such as production of interleukin-10 to suppress the local immune response. © 2001 Wiley-Liss, Inc.
Author supplied keywords
Cite
CITATION STYLE
Shen, L., Chiang, A. K. S., Liu, W. P., Li, G. D., Liang, R. H. S., & Srivastava, G. (2001). Expression of HLA class I, β2-microglobulin, TAP1 and IL-10 in epstein-barr virus-associated nasal NK/T-cell lymphoma: Implications for tumor immune escape mechanism. International Journal of Cancer, 92(5), 692–696. https://doi.org/10.1002/1097-0215(20010601)92:5<692::AID-IJC1237>3.0.CO;2-Z
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.